Limits...
Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.

Hong J, Woo HS, Kim H, Ahn HK, Sym SJ, Park J, Ahn JY, Cho EK, Shin DB, Lee JH - Cancer Sci. (2014)

Bottom Line: This finding was observed irrespective of the status of pre-treatment bone marrow involvement.In multivariate analysis, hemoglobin <10 g/dL was found to be an international prognostic index-independent prognostic factor.Risk of relapse was significantly higher for patients who were still anemic at 6 months after R-CHOP, compared to those who achieved complete recovery from chemotherapy-induced anemia within 6 months.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea.

Show MeSH

Related in: MedlinePlus

Analyses of the impact of anemia on treatment outcomes in a subgroup of patients (group CR6) (n = 87). Kaplan–Meier curves of disease-free survival according to the grade of baseline anemia (a), the mean gap (Δ) between baseline and nadir hemoglobin (Hb) during immunochemotherapy (b), and the normalization of Hb 3 months (c) and 6 months (d) after completion of the planned therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317957&req=5

fig02: Analyses of the impact of anemia on treatment outcomes in a subgroup of patients (group CR6) (n = 87). Kaplan–Meier curves of disease-free survival according to the grade of baseline anemia (a), the mean gap (Δ) between baseline and nadir hemoglobin (Hb) during immunochemotherapy (b), and the normalization of Hb 3 months (c) and 6 months (d) after completion of the planned therapy.

Mentions: Among patients in Group CR6, baseline anemia G ≥ 2 did not showed an association with the difference of DFS (P = 0.356; Fig. 2a).


Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.

Hong J, Woo HS, Kim H, Ahn HK, Sym SJ, Park J, Ahn JY, Cho EK, Shin DB, Lee JH - Cancer Sci. (2014)

Analyses of the impact of anemia on treatment outcomes in a subgroup of patients (group CR6) (n = 87). Kaplan–Meier curves of disease-free survival according to the grade of baseline anemia (a), the mean gap (Δ) between baseline and nadir hemoglobin (Hb) during immunochemotherapy (b), and the normalization of Hb 3 months (c) and 6 months (d) after completion of the planned therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317957&req=5

fig02: Analyses of the impact of anemia on treatment outcomes in a subgroup of patients (group CR6) (n = 87). Kaplan–Meier curves of disease-free survival according to the grade of baseline anemia (a), the mean gap (Δ) between baseline and nadir hemoglobin (Hb) during immunochemotherapy (b), and the normalization of Hb 3 months (c) and 6 months (d) after completion of the planned therapy.
Mentions: Among patients in Group CR6, baseline anemia G ≥ 2 did not showed an association with the difference of DFS (P = 0.356; Fig. 2a).

Bottom Line: This finding was observed irrespective of the status of pre-treatment bone marrow involvement.In multivariate analysis, hemoglobin <10 g/dL was found to be an international prognostic index-independent prognostic factor.Risk of relapse was significantly higher for patients who were still anemic at 6 months after R-CHOP, compared to those who achieved complete recovery from chemotherapy-induced anemia within 6 months.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea.

Show MeSH
Related in: MedlinePlus